August 5, 2025
One of the biggest problems with the cell and gene therapy sector is 99% of them have no earnings! It’s all about hope of a cure…
Earnings are the highlight of the week: Beam Therapeutics (BEAM), Supernus Pharmaceuticals (SUPN) <Acquired Sage Therapeutics (SAGE), AxoGen (AXGN) and Ultragenyx Pharmaceuticals (RARE). Last night release: Cellectis SA (CLLS) and CRISPR Therapeutics (CRSP) <see The Bottom Line>
Pre-open Signals: 2 Positive, 1 Negative and 2 Sell into Strength Indications
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
August 1, 2025
7/24 - Whack-a-mole stock, Harvard Apparatus RT (OTCQB: HRGN) dives -$0.20 or -12.9% to $1.35 with only 200 shares traded.
A question, D. Phone (with its overseer, MSS China’s secret security service) and its sub, Dixintong Technology Group from Beijing, China can’t find a “vehicle” to drop any more $’s to shore-up their lack of cash and runway <52-week range $0.935 to $5.90>?
Remember DST Capital subsidizes OTCQB: HRGN, run by Hong Yu. President of HRGN, Mrs. Bin (Zhao) from Weston, Mass and funded by her husband Lui Dong Hai, chairman of Dixintong Technology Group (D. Phone) in China
Are you sure: No Foreign Corrupt Practices… related to foreign or domestic political activity, or domestic political parties or campaigns from corporate funds?
MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies?
Lest investors forget OTCQB: HRGN was the subject of a Netflix special, “Bad Surgeon: Love Under the Knife”
Short Synopsis (8-K) ...
August 5, 2025
Look at herd of earnings and well, most follow the same with ... net losses <although 3 net incomes out of 12 so far>, they all define their clinical momentum yet, cash positions and those with collaboration revenue stand-out. The cell and gene therapy sector can’t manipulate their runways <i.e., need for capital> and timing is important. Earnings are usually predictable; but investors need to focus on post release performance without … worrying <too much> about follow-on sessions, months and Qs.
Earnings today: Beam Therapeutics (BEAM) and AxoGen (AXGN) <see The Bottom Line>
While the present and future value of RegMed Investors (RMi) earnings sheds light on the cell and gene therapy sector’s “current” acrobatics
Never leave an investor uninformed!
August 1, 2025
7/24 - Whack-a-mole stock, Harvard Apparatus RT (OTCQB: HRGN) dives -$0.20 or -12.9% to $1.35 with only 200 shares traded. A question, D. Phone (with its overseer, MSS China’s secret security service) and its sub, Dixintong Technology Group from Beijing, China can’t find a “vehicle” to drop any more $’s to shore-up their lack of cash and runway <52-week range $0.935 to $5.90>? What happened to the reverse split and why replace it with an immediate private placement? Remember DST Capital subsidizes OTCQB: HRGN, run by Hong Yu. President of HRGN, Mrs. Bin (Zhao) from Weston, Mass and funded by her husband Lui Dong Hai, chairman of Dixintong Technology Group (D. Phone) in China PONZI Scheme, another private placement of 1.25 M shares priced at $1.60 Are you sure: No Foreign Corrupt Practices… related to foreign or domestic political activity, or domestic political parties or campaigns from corporate funds? MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies? Lest investors forget OTCQB: HRGN was the subject of a Netflix special, “Bad Surgeon: Love Under the Knife” Short Synopsis (8-K) ...
August 1, 2025
PRME closed Friday at $4.04 ... And the full exercise of the 5.7 K underwriters’ option at $3.30 per share. The gross proceeds before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 M. TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
June 17, 2025
Gene therapy companies are riding a new waave ... Verve Therapeutics (VERV +$4.79 or +76.31 to $11.06) rallied after the gene editing company agreed to be acquired by Eli Lilly (LLY -$9.13 or -1.15% to $798.28) or $10.50 per share, a premium of 67.5% on the company’s last close. The deal, which is worth up to $1.3 billion, is expected to close in Q3/25. The 2 companies were already partnered on a handful of 1-time treatments for cardiovascular diseases. VERV's leading program would use gene editing to permanently turn off the PCSK9 gene. The gene makes a protein that, when elevated, leads to high cholesterol. LLY also agreed to pay an additional $3 per share in a contingent value right. Lilly will pay the CVR when the first patient receives Verve's leading drug in a U.S. P3 study for atherosclerotic cardiovascular disease.
2 hours 59 min ago
RegMed Investors (RMi) Closing Bell: Whoa …
11 hours 45 min ago
RegMed Investors’ (RMi) pre-open: Think about it …
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
